Pulmatrix announced a definitive merger agreement with Eos SENOLYTIX, a biotechnology company focused on gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases. Upon completion of the transaction, the combined entity will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker symbol “EOSX.”
The deal is supported by $19 million in aggregate gross proceeds from concurrent private financings. This includes a $1 million investment in Pulmatrix from RCM Eos PIPE HOLDINGS LLC and a bridge financing component for Eos, both managed by Rapha Capital Management. The capital will be used to advance Eos’s proprietary MitoXcel platform and its lead clinical candidate, PTC-2105.
PTC-2105 is being developed to treat sarcopenia and sarcopenic obesity by targeting mitochondrial dysfunction, a key biological driver of aging. In preclinical studies, the therapy demonstrated improvements in body composition, including reductions in fat mass, increases in lean muscle mass, and enhanced physical function, without reducing food intake or causing rebound weight gain.
The companies stated that this approach differentiates PTC-2105 from GLP-1 receptor agonists, which primarily focus on weight loss and are often associated with lean mass loss, gastrointestinal side effects, and weight regain after discontinuation. The therapy may also be used alongside GLP-1 treatments to enhance outcomes.
The merger has been unanimously approved by the boards of both companies and is expected to close in mid-2026, subject to shareholder approval and regulatory requirements. Following the transaction, existing Pulmatrix shareholders are expected to own approximately 6% of the combined company, while Eos shareholders, including financing participants and advisors, will hold about 94%.
The combined company aims to position itself as a leader in the emerging field of gerotherapeutics, targeting the root biological mechanisms of aging to improve overall healthspan.
